Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have received a consensus rating of “Hold” from the twenty brokerages that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, twelve have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $123.22.

ZBH has been the subject of a number of analyst reports. BTIG Research cut their price objective on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a report on Thursday, October 3rd. Raymond James cut their price objective on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a report on Monday, October 14th. TD Cowen cut their price target on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a report on Friday, September 6th. Wolfe Research assumed coverage on Zimmer Biomet in a report on Tuesday, September 10th. They issued a “peer perform” rating for the company. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Thursday, October 31st.

Hedge Funds Weigh In On Zimmer Biomet

Institutional investors and hedge funds have recently modified their holdings of the business. Crewe Advisors LLC acquired a new position in shares of Zimmer Biomet in the 1st quarter valued at approximately $31,000. Dunhill Financial LLC boosted its position in Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 218 shares during the last quarter. Ashton Thomas Securities LLC acquired a new position in Zimmer Biomet during the 3rd quarter worth approximately $28,000. Bangor Savings Bank acquired a new position in Zimmer Biomet during the 3rd quarter worth approximately $31,000. Finally, Family Firm Inc. acquired a new position in Zimmer Biomet during the 2nd quarter worth approximately $33,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Up 3.4 %

ZBH opened at $112.54 on Friday. Zimmer Biomet has a fifty-two week low of $101.47 and a fifty-two week high of $133.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The firm’s fifty day moving average price is $106.13 and its two-hundred day moving average price is $110.18. The company has a market capitalization of $22.40 billion, a P/E ratio of 21.40, a P/E/G ratio of 2.02 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.74. The company had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business’s revenue was up 4.1% on a year-over-year basis. During the same period last year, the business earned $1.65 earnings per share. On average, analysts anticipate that Zimmer Biomet will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.85%. Zimmer Biomet’s payout ratio is currently 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.